Your browser doesn't support javascript.
loading
Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic.
Logan, Todd; Simon, Matthew J; Rana, Anil; Cherf, Gerald M; Srivastava, Ankita; Davis, Sonnet S; Low, Ray Lieh Yoon; Chiu, Chi-Lu; Fang, Meng; Huang, Fen; Bhalla, Akhil; Llapashtica, Ceyda; Prorok, Rachel; Pizzo, Michelle E; Calvert, Meredith E K; Sun, Elizabeth W; Hsiao-Nakamoto, Jennifer; Rajendra, Yashas; Lexa, Katrina W; Srivastava, Devendra B; van Lengerich, Bettina; Wang, Junhua; Robles-Colmenares, Yaneth; Kim, Do Jin; Duque, Joseph; Lenser, Melina; Earr, Timothy K; Nguyen, Hoang; Chau, Roni; Tsogtbaatar, Buyankhishig; Ravi, Ritesh; Skuja, Lukas L; Solanoy, Hilda; Rosen, Howard J; Boeve, Bradley F; Boxer, Adam L; Heuer, Hilary W; Dennis, Mark S; Kariolis, Mihalis S; Monroe, Kathryn M; Przybyla, Laralynne; Sanchez, Pascal E; Meisner, Rene; Diaz, Dolores; Henne, Kirk R; Watts, Ryan J; Henry, Anastasia G; Gunasekaran, Kannan; Astarita, Giuseppe; Suh, Jung H.
Afiliación
  • Logan T; Denali Therapeutics, South San Francisco, CA, USA.
  • Simon MJ; Denali Therapeutics, South San Francisco, CA, USA.
  • Rana A; Denali Therapeutics, South San Francisco, CA, USA.
  • Cherf GM; Denali Therapeutics, South San Francisco, CA, USA.
  • Srivastava A; Denali Therapeutics, South San Francisco, CA, USA.
  • Davis SS; Denali Therapeutics, South San Francisco, CA, USA.
  • Low RLY; Denali Therapeutics, South San Francisco, CA, USA.
  • Chiu CL; Denali Therapeutics, South San Francisco, CA, USA.
  • Fang M; Denali Therapeutics, South San Francisco, CA, USA.
  • Huang F; Denali Therapeutics, South San Francisco, CA, USA.
  • Bhalla A; Denali Therapeutics, South San Francisco, CA, USA.
  • Llapashtica C; Denali Therapeutics, South San Francisco, CA, USA.
  • Prorok R; Denali Therapeutics, South San Francisco, CA, USA.
  • Pizzo ME; Denali Therapeutics, South San Francisco, CA, USA.
  • Calvert MEK; Denali Therapeutics, South San Francisco, CA, USA.
  • Sun EW; Denali Therapeutics, South San Francisco, CA, USA.
  • Hsiao-Nakamoto J; Denali Therapeutics, South San Francisco, CA, USA.
  • Rajendra Y; Denali Therapeutics, South San Francisco, CA, USA.
  • Lexa KW; Denali Therapeutics, South San Francisco, CA, USA.
  • Srivastava DB; Denali Therapeutics, South San Francisco, CA, USA.
  • van Lengerich B; Denali Therapeutics, South San Francisco, CA, USA.
  • Wang J; Denali Therapeutics, South San Francisco, CA, USA.
  • Robles-Colmenares Y; Denali Therapeutics, South San Francisco, CA, USA.
  • Kim DJ; Denali Therapeutics, South San Francisco, CA, USA.
  • Duque J; Denali Therapeutics, South San Francisco, CA, USA.
  • Lenser M; Denali Therapeutics, South San Francisco, CA, USA.
  • Earr TK; Denali Therapeutics, South San Francisco, CA, USA.
  • Nguyen H; Denali Therapeutics, South San Francisco, CA, USA.
  • Chau R; Denali Therapeutics, South San Francisco, CA, USA.
  • Tsogtbaatar B; Denali Therapeutics, South San Francisco, CA, USA.
  • Ravi R; Denali Therapeutics, South San Francisco, CA, USA.
  • Skuja LL; Denali Therapeutics, South San Francisco, CA, USA.
  • Solanoy H; Denali Therapeutics, South San Francisco, CA, USA.
  • Rosen HJ; Memory and Aging Center, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; On behalf of the ALLFTD investigators.
  • Boeve BF; On behalf of the ALLFTD investigators; Department of Neurology, College of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Boxer AL; Memory and Aging Center, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; On behalf of the ALLFTD investigators.
  • Heuer HW; Memory and Aging Center, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; On behalf of the ALLFTD investigators.
  • Dennis MS; Denali Therapeutics, South San Francisco, CA, USA.
  • Kariolis MS; Denali Therapeutics, South San Francisco, CA, USA.
  • Monroe KM; Denali Therapeutics, South San Francisco, CA, USA.
  • Przybyla L; Denali Therapeutics, South San Francisco, CA, USA.
  • Sanchez PE; Denali Therapeutics, South San Francisco, CA, USA.
  • Meisner R; Denali Therapeutics, South San Francisco, CA, USA.
  • Diaz D; Denali Therapeutics, South San Francisco, CA, USA.
  • Henne KR; Denali Therapeutics, South San Francisco, CA, USA.
  • Watts RJ; Denali Therapeutics, South San Francisco, CA, USA.
  • Henry AG; Denali Therapeutics, South San Francisco, CA, USA.
  • Gunasekaran K; Denali Therapeutics, South San Francisco, CA, USA.
  • Astarita G; Denali Therapeutics, South San Francisco, CA, USA; Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, USA.
  • Suh JH; Denali Therapeutics, South San Francisco, CA, USA.
Cell ; 184(18): 4651-4668.e25, 2021 09 02.
Article en En | MEDLINE | ID: mdl-34450028
ABSTRACT
GRN mutations cause frontotemporal dementia (GRN-FTD) due to deficiency in progranulin (PGRN), a lysosomal and secreted protein with unclear function. Here, we found that Grn-/- mice exhibit a global deficiency in bis(monoacylglycero)phosphate (BMP), an endolysosomal phospholipid we identified as a pH-dependent PGRN interactor as well as a redox-sensitive enhancer of lysosomal proteolysis and lipolysis. Grn-/- brains also showed an age-dependent, secondary storage of glucocerebrosidase substrate glucosylsphingosine. We investigated a protein replacement strategy by engineering protein transport vehicle (PTV)PGRN-a recombinant protein linking PGRN to a modified Fc domain that binds human transferrin receptor for enhanced CNS biodistribution. PTVPGRN rescued various Grn-/- phenotypes in primary murine macrophages and human iPSC-derived microglia, including oxidative stress, lysosomal dysfunction, and endomembrane damage. Peripherally delivered PTVPGRN corrected levels of BMP, glucosylsphingosine, and disease pathology in Grn-/- CNS, including microgliosis, lipofuscinosis, and neuronal damage. PTVPGRN thus represents a potential biotherapeutic for GRN-FTD.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Encéfalo / Enfermedades por Almacenamiento Lisosomal / Progranulinas Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Cell Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Encéfalo / Enfermedades por Almacenamiento Lisosomal / Progranulinas Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Cell Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos